Letter to shareholders — Rights Issue

Sep 25, 2018
Posted in: Investor updates

Home » Letter to shareholders — Rights Issue

Letter to shareholders — Rights Issue

Sep 25, 2018
Posted in: Investor updates

Imagion Biosystems has lodged the announcement “Pro-Rata Non-Renounceable Rights Issue” with the Australian Securities Exchange.
View the announcement “Pro-Rata Non-Renounceable Rights Issue.”

Positive independent review sets priority path to market for MagSense® Technology

February 5, 2023

Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance

Quarterly Activity Report – Quarter Ending 31 December 2022

January 30, 2023

Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with

Quarterly Activity Report – Quarter Ending 30 September 2022

October 28, 2022

Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Letter to shareholders — Rights Issue

Letter to shareholders — Rights Issue

Related Articles

Positive independent review sets priority path to market for MagSense® Technology

Quarterly Activity Report – Quarter Ending 31 December 2022

Quarterly Activity Report – Quarter Ending 30 September 2022

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list